Previous close | 63.23 |
Open | 63.42 |
Bid | 64.85 x 900 |
Ask | 64.90 x 1100 |
Day's range | 63.30 - 64.75 |
52-week range | 56.56 - 85.97 |
Volume | 9,761,404 |
Avg. volume | 9,124,683 |
Market cap | 81.201B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 659.39 |
EPS (TTM) | 0.10 |
Earnings date | 28 Apr 2021 - 03 May 2021 |
Forward dividend & yield | 2.84 (4.39%) |
Ex-dividend date | 12 Mar 2021 |
1y target est | 74.54 |
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).